Research-use-only reference. This page documents what the scientific literature reports about sermorelin; it is not medical advice and not a recommendation to use sermorelin in humans. For any health decision, consult a qualified healthcare professional.
People searching “sermorelin side effects” usually want a straight answer to one question: how risky is this peptide, really? Sermorelin is a synthetic fragment of growth hormone-releasing hormone (GHRH 1-29) that prompts the pituitary to release the body’s own growth hormone. The honest one-line summary: in the small, mostly older human studies that exist, sermorelin and closely related GHRH(1-29) analogs were generally well tolerated, with mild, transient injection-site reactions as the most common complaint — but the human safety database is thin, dated, and does not cover long-term use in healthy adults, so “well tolerated in short trials” is not the same as “proven safe.”
Documented side effects
Below, effects are organized by what the evidence actually shows. We flag whether each signal comes from clinical human trials, a review synthesizing clinical plus self-reported/anecdotal data, or a theoretical mechanism. No percentages are given because the retrieved human trials reported adverse events qualitatively, not as reliable frequencies for sermorelin specifically — any site quoting a precise “X% of users” figure should be treated with suspicion.
| Effect | Frequency / severity | Evidence source & type |
|---|---|---|
| Injection-site reactions (pain, redness, swelling) | Most commonly reported; mild and transient | Munafo 2005, Phase I RCT of PEG-GHRH, a long-acting GHRH(1-29) derivative (clinical); Dominikowski 2026 (review) |
| Impaired glucose tolerance / dysglycaemia | Seen in older adults after repeated dosing; metabolically meaningful, not trivial | Munafo 2005, in elderly subjects (clinical); Dominikowski 2026 (review) |
| Transient lipid changes (hyperlipidemia) | Reported in one 16-week trial; resolved by study end | Khorram 1997, RCT of a sermorelin-class GHRH(1-29) analog (clinical) |
| Increased skin thickness | Documented over 16 weeks; a growth hormone/IGF-1 tissue effect, generally benign | Khorram 1997 (clinical) |
| Endocrine shifts (prolactin/cortisol changes, appetite change), fluid retention, myalgia/arthralgia | Reported across GH-axis peptides including sermorelin; clinical + anecdotal | Dominikowski 2026 (review) |
| Mitogenic / cancer-promotion concern (from raised GH & IGF-1) | Not observed in the trials retrieved; biologically plausible, unproven, unquantified | Dominikowski 2026; Walker 2006 (theoretical / mechanistic) |
The single largest and longest sermorelin-specific human safety readout is old: in 110 growth hormone-deficient children treated with sermorelin (GHRH 1-29) for up to one year, it was “well tolerated,” with no adverse changes in blood chemistry or fasting glucose (Thorner 1996). That is reassuring as far as it goes — but it studied children with a diagnosed deficiency, not healthy adults using sermorelin for body composition, “anti-aging,” or performance. The serious signals to keep in view are therefore the metabolic one (glucose tolerance can worsen, especially in older users; Munafo 2005) and the theoretical mitogenic one, because chronically elevating growth hormone and IGF-1 is the mechanism through which a cancer-promotion risk is hypothesized (Dominikowski 2026; Walker 2006). Neither should be minimized just because trials were short.
Who is at higher risk / contraindications
- People with a history of cancer or active malignancy. Because sermorelin raises GH/IGF-1, the theoretical concern that it could stimulate mitogenic (cell-dividing) activity applies most to this group (Dominikowski 2026; Walker 2006). The risk is unproven but biologically plausible — a reason for caution, not reassurance.
- People with prediabetes, diabetes, or impaired glucose tolerance. Repeated GHRH-analog dosing worsened glucose tolerance in older subjects (Munafo 2005), and dysglycaemia is a recognized class effect (Dominikowski 2026).
- Older adults. The glucose-tolerance signal appeared specifically in elderly participants on repeated dosing (Munafo 2005).
- Anyone using unregulated “research-grade” or compounded material. There is no active FDA-labeled sermorelin product listed in DailyMed as of 2026; supply is largely compounded or sold research-only, so purity, dose accuracy, and sterility are not guaranteed (Dominikowski 2026 emphasizes this uncertainty). Contaminated or mislabeled product is its own risk, separate from the molecule.
- Pregnancy and breastfeeding. No human safety data were identified; standard practice is avoidance.
What we do NOT know
The gaps are large and are themselves a risk, not a green light:
- No long-term safety data in healthy adults. The human evidence is small, mostly from the 1990s–2000s, and centered on deficiency states or short elderly studies. Dominikowski 2026 explicitly stratifies these GH-axis peptides by evidence tier and highlights how much remains uncertain.
- Scarce modern trials. On ClinicalTrials.gov, several GHRH-in-elderly studies were small or terminated early (e.g., NCT01410799, NCT00807365), so robust long-duration data simply do not exist for the way sermorelin is now commonly used.
- Unquantified mitogenic/cancer risk. No retrieved study demonstrates it, but none rules it out over years of use; it remains theoretical and unmeasured (Dominikowski 2026; Walker 2006).
- Product-quality unknowns. With no current regulated product, “unknown long-term safety” is compounded by “unknown what is actually in the vial.”
Treat unknown long-term safety as a genuine limitation. Absence of documented harm in short studies is not evidence of safety over years.
Dosage & handling reference
For laboratory documentation of reconstitution and handling figures, see our Sermorelin dosage reference and the peptide dosage calculator. These are research-documentation tools only — they describe how quantities are calculated in a laboratory context and are not human-use instructions. Nothing on these pages should be read as a recommendation to inject sermorelin; dosing decisions for any person belong with a qualified clinician.
FAQ
Is sermorelin safe?
In short, dated human trials it was generally well tolerated, with mild transient injection-site reactions as the main complaint (Munafo 2005; Thorner 1996). But there are no long-term studies in healthy adults, the metabolic (glucose) signal is real, a theoretical cancer-promotion concern is unresolved, and much of today’s supply is unregulated. “Generally tolerated in old, short studies” is the accurate ceiling on that claim — not “proven safe.”
What is the most common side effect?
Injection-site reactions — pain, redness, or swelling that is typically mild and short-lived (Munafo 2005). More consequential than that cosmetic effect are the metabolic changes: worsened glucose tolerance in older users (Munafo 2005) and transient lipid changes (Khorram 1997).
Does sermorelin cause cancer?
No retrieved study shows that it does. However, because sermorelin raises growth hormone and IGF-1, a mitogenic (cancer-promoting) effect is biologically plausible and has not been quantified over long-term use (Dominikowski 2026; Walker 2006). Anyone with a personal or family history of cancer should not use it without medical supervision.
This page is for research reference and general education only. It is not medical advice, diagnosis, or treatment. Sermorelin is not an FDA-approved therapy for anti-aging, weight loss, or athletic performance. Consult a licensed healthcare professional before making any medical decision.
